er-positive

Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer

AETOSWire October 12, 2022

CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence...

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer

Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0682 in ER-Positive Breast Cancer

AETOSWire April 4, 2022

BROOKLYN, N.Y. & SHANGHAI–(BUSINESS WIRE/AETOSWire)– Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence...